|
August 3-5, 2009
(August 3-4 main conference)
Is Oligonucleotide Therapeutics the Next Big Thing After Monoclonal Antibodies?
The conference attempts to answer the question "Is Oligonucleotide Therapeutics the next big thing after Monoclonal Antibodies?" By presenting the mechanisms of actions and challenges in delivery, efficacy, toxicity and specificity underlying the various oligonucleotide modalities (siRNA, miRNA, antisense and aptamars) and showcasing the various stages of drug development to-date, the conference will illustrate how oligonucleotide therapeutics have the potential to become the Next Big Thing in drug discovery and development.
Why You Should Attend:
- Meet Who's Who in the Oligonucleotide Industry
- Find out how leading minds of the industry are revolutionizing the industry with innovations in delivery, breakthroughs in understanding of mechanisms, efficacy and toxicity
- Hear the latest results of oligos in the clinic
Confirmed Speakers and Sessions
(As of March 16, 2009)
Here is Sneak Peak at the Agenda ...Confirmed Speakers and Sessions Include:
Keynote Address: RNAi Therapeutics - the Next Big Thing after Monoclonal Antibodies?
- Cy Stein, Professor, Urology & Molecular Pharmacology, Albert Einstein College of Medicine
Industry Keynote: 30 Years of Targeting RNA: A Retrospective
- Tod Woolf, Ph.D., President and CEO, RXi Pharmaceuticals Corporation
Industry Leadership Forum: RNA Therapeutics - Are We Leveraging On The Promise?
- John Maraganore, Ph.D., Chief Executive Officer, Alnylam
- Klaus Giese, Ph.D., Chief Scientific Officer, Vice President, Research, Silence Therapeutics AG
- Paul Burke, Ph.D., Executive Director, RNA Therapeutics, Merck & Co., Inc.
- Tod Woolf, Ph.D., President and CEO, RXi Pharmaceuticals Corporation
Delivery Challenges and Novel Delivery Systems
- Ian MacLachlan, Ph.D., Executive Vice President & Chief Scientific Officer, Tekmira Pharmaceuticals Corp.
- Gary R. Ostroff, Ph.D., Research Professor, University of Massachusetts Medical School
- Thomas Schluep, Ph.D., Chief Scientific Officer, Calando Pharmaceuticals
- Michael Templin, Ph.D., Discovery Research and Pharmaceutical Development, MDRNA Inc.
- Patrick Lu, Ph.D., President & CEO, Sirnaomics, Inc.
Specificity & Toxicity Considerations in Developing Oligonucleotide Therapeutics
- Satish Chandran, Ph.D., Chief Technology Officer, Pfizer RTC
- Richard S. Geary, Senior Vice President, Development, Isis Pharmaceuticals, Inc.
- Aimee Jackson, Ph.D., Director Drug Discovery, Regulus Therapeutics
Immunomodulation
- Dennis Klinman, Ph.D., M.D., Senior Investigator, Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health
Preclinical & Clinical Development of siRNA, miRNA, Antisense and Aptamars
- Klaus Giese, Ph.D., CSO, VP Research, Silence Therapeutics
- James Thompson, Ph.D., Vice President, Pharmaceutical Development, Quark Pharmaceuticals, Inc.
- Dmitry Samarsky, Ph.D., Vice President, Technology Development, RXi Pharmaceuticals
- John Rossi, Ph.D., Professor & Chairman, Molecular Biology, Beckman Research Institute of The City of Hope, City of Hope Graduate School of Biological Sciences
- Francois Major, Ph.D., Professor, Computer Science, Institute for Research in Immunology and Cancer, Universite de Montreal
- William S. Marshall, Ph.D., President & CEO, Miragen Therapeutics
- Matt Winkler, Ph.D., Chief Executive Officer, Asuragen/Mirna Therapeutics
- Henrik Orum, Ph.D., Vice President & CSO, Santaris Pharma
- Mario Germano Giuliani, Ph.D., President & CEO, Giuliani SPA
- Kristin M. Thompson, Ph.D., Associate Director, Aptamer Discovery
Plus: an interactive Attendee/Speaker Chat Sessions that enables attendees to participate actively on topics including:
- Regulatory Updates - What's the Status, Relationship & Treatment of RNAi Compounds?
- Maximizing Therapeutic Oligo Manufacturing Efficiency via Customer and CMO Partnerships
- Delivery Innovations and Breakthroughs
- Current & Future Developments of miRNA
- RNAi for Target Validation
- Challenges and Limitations of In Vivo Models for Oligo Therapeutics
- Survey of the IP Landscape
Announcing "Rising TIDES - Development of Oligonucleotide Therapeutics in Japan", a post-conference workshop on Wednesday, August 5.
Find out what are the opportunities and challenges of developing oligonucleotide-based thereapeutics in Japan, and how you can enter the burgeoning market.
Scientific Advisory Board
Gary Carter, Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc.
Aimee Jackson, Ph.D., Director Drug Discovery, Regulus Therapeutics
Troels Koch, Ph. D., Vice President Research, Santaris Pharma A/S
Dmitry Samarsky, Ph.D., VP, Technology Development, RXi Pharmaceuticals
James Thompson, Ph.D., Vice President, Pharmaceutical Development, Quark Pharmaceuticals
|
